Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ASP0739||aAVC ASP0739|aAVCs ASP0739|ASP 0739|ASP-0739||ASP0739 are human artificial adjuvant vector cells loaded with the CD1d ligand alpha-galactosylceramide and modified to express the tumor associated antigen NY-ESO-1 (CTAG1B), which potentially induce activation of immune cells, and cytotoxic T-cell mediated response against tumor cells expressing NY-ESO-1 (NCI Thesaurus).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04939701||Phase Ib/II||ASP0739 + Pembrolizumab ASP0739||Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants||Recruiting||USA||0|